Arialys Therapeutics' precision medicine has shown preclinical potential to address the underlying cause of anti-NMDA ...

Initially identified as a proto-oncogene, c-Fos is essential for neural activity, synaptic plasticity, and stress responses. While its transient expression supports memory formation in healthy brains, ...

Mayo Clinic's Molecular Neurotherapeutics Lab cloned a neuron-specific tau kinase from the human brain tissue cDNA library and characterized the role of TTBK1 in tau aggregation.

In a small pilot trial published in a journal, researchers found that creatine monohydrate may help improve cognitive function in individuals with Alzheimer's Disease. It’s hard to cruise your ...

Having noted that overactivated NMDA glutamate receptors cause repetitive behaviors, the research team administered a drug called memantine, a commercially available treatment for Alzheimer's ...

Three classes of medications have been approved by the Food and Drug Administration (FDA) for the treatment of the cognitive symptoms of Alzheimer's. They include cholinesterase inhibitors, N-methyl D ...

In Alzheimer's disease, acetylcholine activity is low. These medications help by increasing acetylcholine levels. Memantine works by preventing glutamate from attaching to the N-methyl-D-aspartate ...

it’s known as early onset Alzheimer’s disease (EOAD). Memantine is an NMDA receptor antagonist. These medications work by blocking N-methyl-D-aspartate (NMDA) receptors and reducing excess ...

AXS-05 (dextromethorphan-bupropion) is a novel, oral, investigational N-methyl-D-aspartate (NMDA) receptor antagonist, sigma-1 agonist, and aminoketone CYP2D6 inhibitor under development for the ...

submission for AXS-05 in Alzheimer’s disease agitation. AXS-05 (dextromethorphan-bupropion) is a novel, oral, investigational NMDA receptor antagonist, sigma-1 agonist, and aminoketone CYP2D6 ...

Alzheimer’s disease is the most common form of dementia. Anjali Patel, DO, a cognitive neurologist at Atlantic Health System, shares more. Alzheimer’s disease is a progressive neurological disorder ...

NMDA receptors are found throughout the central ... blocking these receptors can also treat the agitation caused by Alzheimer’s. Rexulti, across all of its approved indications, generated ...